<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617717</url>
  </required_header>
  <id_info>
    <org_study_id>153850</org_study_id>
    <nct_id>NCT04617717</nct_id>
  </id_info>
  <brief_title>Personalized Treatment for Patients With Premature Ventricular Beats</brief_title>
  <official_title>Personalized Treatment for Patients With Premature Ventricular Beats</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frequent premature ventricular beats (PVBs) are common, negatively affects the quality of&#xD;
      life for many patients, and can lead to impaired contractile function. Rule-out of structural&#xD;
      heart disease is key in the assessment of PVBs. Cardiac MR has a high sensitivity for&#xD;
      structural heart disease, but the diagnostic gain from this resource-demanding procedure in&#xD;
      the work-up of patients with PVBs is unknown. There is a need to establish the role of MR in&#xD;
      the evaluation of patients with PVBs to improve diagnostic efficacy, establish treatment&#xD;
      strategies, and promote further research. This project will answer three key questions: 1)&#xD;
      What is the diagnostic gain from cardiac MR in patients with PVBs? 2) Is MR the real gold&#xD;
      standard to rule-out structural heart disease in patients with PVBs? 3) Can non-invasive&#xD;
      heart rate parameters guide the strategy for induction of PVBs during invasive&#xD;
      electrophysiological procedures?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2040</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI-based evidence of structural heart disease</measure>
    <time_frame>3-5 years</time_frame>
    <description>Evidence of structural heart disease from MRI compared to echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PVC induction vs PVC/HR-relationship</measure>
    <time_frame>3-5 years</time_frame>
    <description>Correlation of method for induction of PVCs during invasive procedure vs PVC/HR relationship during CPET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EPS-based evidence of structural heart disease</measure>
    <time_frame>3-5 years</time_frame>
    <description>Evidence of structural heart disease from invasive electrophysiology vs MRI and echo</description>
  </primary_outcome>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Ventricular Premature Complexes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive cardiac electrophysiological study and ablation therapy</intervention_name>
    <description>Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiopulmonary exercise testing</intervention_name>
    <description>Standard ergometer bicycle test</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI with cine-imaging and late-gadolinium enhancement</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Holter monitoring</intervention_name>
    <description>24h 5 lead or 12 lead ECG recording</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transthoracic echocardiography</intervention_name>
    <description>2D echocardiography</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary angiography</intervention_name>
    <description>Conventional invasive coronary angiography or CT angiography as indicated</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to PVC ablation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients referred for PVC ablation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathis K Stokke, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathis K Stokke, MD PhD</last_name>
    <phone>90696883</phone>
    <phone_ext>+47</phone_ext>
    <email>m.k.stokke@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0672</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathis K Stokke, MD PhD</last_name>
      <phone>90696883</phone>
      <phone_ext>+47</phone_ext>
      <email>m.k.stokke@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Mathis Korseberg Stokke</investigator_full_name>
    <investigator_title>Associate Professor and Consultant Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

